[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576147":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":50,"collaborators":18,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":18,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"HCL, B-raf V600E-mutated patients","For each patient only pheripheral and medullary blood sample and medullary biospy will be collected",[12],"Other: Peripheral and BM blood sample",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Peripheral and BM blood sample","Peripheral and BM blood samples will be analyzed with the ddPCR method",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Pier Luigi Zinzani, MD","PRINCIPAL_INVESTIGATOR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","+390512143680","pierluigi.zinzani@unibo.it",{"name":29,"role":25,"phone":30,"phoneExt":18,"email":31},"Alessandro Broccoli, MD","+39 0512143680","Alessandro.broccoli@studio.unibo.it",[33],{"facility":34,"status":35,"city":36,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"IRCCS Azienda Ospedaliero - Universitaria di Bologna","RECRUITING","Bologna","40138","Italy","IT",{"type":41,"coordinates":42},"Point",[43,44],11.33875,44.49381,{"lat":44,"lon":43},[47,48,49],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},{"name":29,"role":25,"phone":30,"phoneExt":18,"email":31},{"name":21,"role":25,"phone":18,"phoneExt":18,"email":18},{"type":51,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100576147","assessment-of-disease-burden-in-hairy-cell-leukemia-100576147",false,"NCT06781515","Assessment of Disease Burden in Hairy Cell Leukemia","BRAF","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of HCL patients:\n\n   1. newly diagnosed and candidates for first-line cytoreductive treatment with analogues purines or\n   2. in relapse after a previous line of treatment, with indication for rescue therapy (repetition of a purine analogue; use of targeted or innovative drugs), except splenectomy or\n   3. in CR for at least 5 years after a first line of treatment, in the absence of clinical alterations indicative of a state of hematological relapse, or in any case in the absence of an indication for a new line of cytoreductive therapy (time-to-next treatment exceeding 5 years).\n2. Age ≥ 18 years at enrollment\n3. Signature of written informed consent\n\nExclusion Criteria:\n\n1\\. Concomitant second malignancy.","ALL","18 Years",{"count":62,"type":63},45,"ESTIMATED","INTERVENTIONAL",[66],"NA","Drug-free, single-center, prospective observational pilot study in hairy Cell Leukemia patients",[69],"Hairy Cell Leukemia","2025-01-13",{"date":72,"type":73},"2025-01-17","ACTUAL",{"date":75,"type":63},"2025-01",{"date":77,"type":63},"2025-11",{"name":5,"class":6},1]